ITGA2, LAMB3, and LAMC2 may be the potential therapeutic targets in pancreatic ductal adenocarcinoma: an integrated bioinformatics analysis.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
18 05 2021
Historique:
received: 31 03 2021
accepted: 05 05 2021
entrez: 19 5 2021
pubmed: 20 5 2021
medline: 9 11 2021
Statut: epublish

Résumé

Pancreatic ductal adenocarcinoma (PDAC) is the most common form of pancreatic cancer with an abysmal prognosis rate over the last few decades. Early diagnosis and prevention could effectively combat this malignancy. Therefore, it is crucial to discover potential biomarkers to identify asymptomatic premalignant or early malignant tumors of PDAC. Gene expression analysis is a powerful technique to identify candidate biomarkers involved in disease progression. In the present study, five independent gene expression datasets, including 321 PDAC tissues and 208 adjacent non-cancerous tissue samples, were subjected to statistical and bioinformatics analysis. A total of 20 differentially expressed genes (DEGs) were identified in PDAC tissues compared to non-cancerous tissue samples. Gene ontology and pathway enrichment analysis showed that DEGs were mainly enriched in extracellular matrix (ECM), cell adhesion, ECM-receptor interaction, and focal adhesion signaling. The protein-protein interaction network was constructed, and the hub genes were evaluated. Collagen type XII alpha 1 chain (COL12A1), fibronectin 1 (FN1), integrin subunit alpha 2 (ITGA2), laminin subunit beta 3 (LAMB3), laminin subunit gamma 2 (LAMC2), thrombospondin 2 (THBS2), and versican (VCAN) were identified as hub genes. The correlation analysis revealed that identified hub genes were significantly interconnected. Wherein COL12A1, FN1, ITGA2, LAMB3, LAMC2, and THBS2 were significantly associated with PDAC pathological stages. The Kaplan-Meier survival plots revealed that ITGA2, LAMB3, and LAMC2 expression were inversely correlated with a prolonged patient survival period. Furthermore, the Human Protein Atlas database was used to validate the expression and cellular origins of hub genes encoded proteins. The protein expression of hub genes was higher in pancreatic cancer tissue than in normal pancreatic tissue samples, wherein ITGA2, LAMB3, and LAMC2 were exclusively expressed in pancreatic cancer cells. Pancreatic cancer cell-specific expression of these three proteins may play pleiotropic roles in cancer progression. Our results collectively suggest that ITGA2, LAMB3, and LAMC2 could provide deep insights into pancreatic carcinogenesis molecular mechanisms and provide attractive therapeutic targets.

Identifiants

pubmed: 34007003
doi: 10.1038/s41598-021-90077-x
pii: 10.1038/s41598-021-90077-x
pmc: PMC8131351
doi:

Substances chimiques

Cell Adhesion Molecules 0
ITGA2B protein, human 0
Integrin alpha2 0
LAMC2 protein, human 0
Laminin 0
RNA, Messenger 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

10563

Références

Genes Dev. 2016 Feb 15;30(4):355-85
pubmed: 26883357
Pharmacogenomics. 2016 Jul;17(10):1129-1143
pubmed: 27359067
J Cell Sci. 1995 Apr;108 ( Pt 4):1629-37
pubmed: 7615681
Nat Rev Mol Cell Biol. 2014 Dec;15(12):802-12
pubmed: 25355505
BMC Cancer. 2016 Aug 12;16:632
pubmed: 27520560
World J Surg Oncol. 2018 Nov 14;16(1):223
pubmed: 30428899
Nucleic Acids Res. 2016 Jul 8;44(W1):W147-53
pubmed: 27190236
Cancer Med. 2018 Feb;7(2):525-535
pubmed: 29322643
PLoS One. 2012;7(2):e31507
pubmed: 22363658
Hepatogastroenterology. 2008 Nov-Dec;55(88):2016-27
pubmed: 19260470
Science. 2017 Aug 18;357(6352):
pubmed: 28818916
Clin Cancer Res. 2012 Aug 15;18(16):4266-76
pubmed: 22896693
Med Sci Monit. 2018 Apr 19;24:2368-2376
pubmed: 29671412
Biol Proced Online. 2018 May 1;20:10
pubmed: 29743821
J Exp Clin Cancer Res. 2019 Dec 9;38(1):485
pubmed: 31818309
Cancer Res. 2020 Apr 1;80(7):1461-1474
pubmed: 32029550
Nat Protoc. 2009;4(1):44-57
pubmed: 19131956
Nucleic Acids Res. 2015 Jan;43(Database issue):D447-52
pubmed: 25352553
Medicine (Baltimore). 2019 Jan;98(2):e14074
pubmed: 30633213
BMC Bioinformatics. 2015 May 22;16:169
pubmed: 25994840
J Exp Med. 2017 Mar 6;214(3):579-596
pubmed: 28232471
Med Sci Monit. 2020 Apr 01;26:e921769
pubmed: 32235821
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Nucleic Acids Res. 2019 Jul 2;47(W1):W556-W560
pubmed: 31114875
J BUON. 2018 Jul-Aug;23(4):891-901
pubmed: 30358191
Nat Med. 2013 Nov;19(11):1410-22
pubmed: 24202394
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Nucleic Acids Res. 2021 Jan 8;49(D1):D545-D551
pubmed: 33125081
Cancer Cell Int. 2018 Dec 22;18:214
pubmed: 30598639
Cancers (Basel). 2018 Sep 06;10(9):
pubmed: 30200666
Front Oncol. 2015 Oct 20;5:224
pubmed: 26539408
Cancer Res. 2016 Jul 1;76(13):3838-50
pubmed: 27197190
Oncol Lett. 2018 Aug;16(2):2453-2461
pubmed: 30013637
Proc Natl Acad Sci U S A. 2019 Sep 24;116(39):19609-19618
pubmed: 31484774
Oncol Rep. 2017 Nov;38(5):2607-2618
pubmed: 28901457
Cold Spring Harb Perspect Biol. 2012 Jan 01;4(1):a004903
pubmed: 21937732
Cancer Res. 2020 May 15;80(10):1991-2003
pubmed: 32098780
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Genes Dis. 2018 Dec 31;6(1):16-24
pubmed: 30906828
Asian Pac J Cancer Prev. 2015;16(6):2561-7
pubmed: 25824797
Cancer Med. 2019 Jul;8(7):3592-3603
pubmed: 31066497
PeerJ. 2020 Jun 15;8:e9301
pubmed: 32587798
Mol Med Rep. 2019 Aug;20(2):1901-1914
pubmed: 31257501
Clin Cancer Res. 2017 Dec 1;23(23):7412-7425
pubmed: 29196495
Semin Cancer Biol. 2020 May;62:166-181
pubmed: 31415910
Nucleic Acids Res. 2011 Jan;39(Database issue):D1002-4
pubmed: 21071405

Auteurs

Shajedul Islam (S)

Advanced Research Promotion Center, Health Sciences University of Hokkaido, 1757 Kanazawa, Ishikari-Tobetsu, Hokkaido, 061-0293, Japan.

Takao Kitagawa (T)

Advanced Research Promotion Center, Health Sciences University of Hokkaido, 1757 Kanazawa, Ishikari-Tobetsu, Hokkaido, 061-0293, Japan.

Byron Baron (B)

Centre for Molecular Medicine and Biobanking, University of Malta, Msida, MSD 2080, Malta.

Yoshihiro Abiko (Y)

Division of Oral Medicine and Pathology, Department of Human Biology and Pathophysiology, School of Dentistry, Health Sciences University of Hokkaido, 1757 Kanazawa, Ishikari-Tobetsu, Hokkaido, 061-0293, Japan.

Itsuo Chiba (I)

Division of Disease Control and Molecular Epidemiology, Department of Oral Growth and Development, School of Dentistry, Health Sciences University of Hokkaido, 1757 Kanazawa, Ishikari-Tobetsu, Hokkaido, 061-0293, Japan.

Yasuhiro Kuramitsu (Y)

Advanced Research Promotion Center, Health Sciences University of Hokkaido, 1757 Kanazawa, Ishikari-Tobetsu, Hokkaido, 061-0293, Japan. climates@hoku-iryo-u.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH